

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4762500

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	BIONTECH AG	12/28/2017
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	BIONTECH RNA PHARMACEUTICALS GMBH	
<b>Street Address:</b>	AN DER GOLDGRUBE 12	
<b>City:</b>	MAINZ	
<b>State/Country:</b>	GERMANY	
<b>Postal Code:</b>	55131	
<b>PROPERTY NUMBERS Total: 1</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Patent Number:</b>	9295717	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(202)824-3001	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	202-824-3000	
<b>Email:</b>	bwptopat@bannerwitcoff.com, jhazzard@bannerwitcoff.com	
<b>Correspondent Name:</b>	BANNER & WITCOFF, LTD.	
<b>Address Line 1:</b>	1100 13TH STREET, NW	
<b>Address Line 2:</b>	SUITE 1200	
<b>Address Line 4:</b>	WASHINGTON, D.C. 20005	
<b>ATTORNEY DOCKET NUMBER:</b>	008836.00001	
<b>NAME OF SUBMITTER:</b>	SARAH A. KAGAN	
<b>SIGNATURE:</b>	/Sarah A. Kagan/	
<b>DATE SIGNED:</b>	01/05/2018	
<b>Total Attachments: 2</b>		
source=Executed Assignment#page1.tif		
source=Executed Assignment#page2.tif		

## PATENT ASSIGNMENT

U.S. Patent No: 9,295,717

This patent is currently owned by BioNTech AG, Uniwersytet Warszawski, and TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbH. THIS PATENT ASSIGNMENT ("Assignment") is made by BioNTech AG, (referred to hereinafter as the "Assignor") and BioNTech RNA Pharmaceuticals GmbH, (referred to hereinafter as the "Assignee"), each at An der Goldgrube 12, 55131 Mainz, Germany.

NOW, THEREFORE, in exchange for good and valuable consideration in hand paid, the receipt, adequacy, and sufficiency of which are hereby acknowledged, the Assignor hereby assigns to the Assignee, its successors and assigns, its entire right, title and interest in and to the inventions and improvements disclosed in a United States patent application entitled "VACCINE COMPOSITION COMPRISING 5'-CAP MODIFIED RNA" filed on April 23, 2012, in the United States Patent and Trademark Office as Serial No. 13/388,560 (referred to hereinafter as the "Application"), and in any and all other (provisional or non-provisional) applications, both United States and other countries, based thereon or that claim priority thereto, including any continuation, continuation-in-part, or divisional application that the Assignor may file, either solely or jointly with others, and in any and all Letters Patent of the United States and other countries that may be obtained on any of said Applications, and in any reexamination, renewal, substitution, reissue or extension of such applications or patents, and every priority right that is or may be predicated upon or arise from said inventions, improvements, applications, and Letters Patent.

The Assignor hereby authorizes the Assignee, its successors and assigns, to file patent applications in any or all countries for any or all of said inventions and improvements in our name or in the name of the Assignee, its successors and assigns, or otherwise as said Assignee, its successors and assigns, may deem advisable, under the International Convention or otherwise. The Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks to issue any Letters Patent to said Assignee, its successors and assigns.

By virtue of a separate Assignment of the Applications executed by Johannes Gutenberg-Universität Mainz to BioNTech AG, executed on November 26, 2014, the Assignor warrants to be a co-owner of the right, title and interest in said invention or improvements and to have the right to make this Assignment, and further warrants that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.

The Assignor hereby agrees, upon the request and at the expense of said Assignee, its successors and assigns, to execute any and all continuation, continuation-in-part, divisional, extension, renewal, and substitute applications for said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination, or extension of any Letters Patent that may be granted upon said Applications,

that said Assignee, its successors or assigns may deem necessary or expedient; and to cooperate to the best of the ability of the Assignor with said Assignee, its successors and assigns, in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all acts necessary to obtain said Letters Patent in the United States and foreign countries, and vest all rights therein hereby conveyed in the Assignee, its successors and assigns, whereby said Letters Patent will be held and enjoyed by the said Assignee, its successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the Assignor if this Assignment had not been made.

This Assignment shall be binding upon and shall inure to the benefit of the Assignee and Assignor and their respective successors and assigns.

This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.

BioNTech AG

Date: Dec 18<sup>th</sup>, 2017 Name: Dr. Siek Poethig  
Title: CFO, Managing Director  
Signature: 